Oncology Best Practice: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer
WebcastFaculty
OVERVIEW
Oncology Best Practice: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer is organized by Physicians Education Resource, LLC (PER) and will be held during Oct 31, 2017 - Oct 31, 2018.
The target audience for this medical event is directed toward medical, surgical and radiation oncologists who treat or manage patients with ovarian cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate. This CME Conference has been approved for a maximum of 1.00 AMA PRA Category 1 Credits.
Conference Overview :
New clinical treatment options for patients with ovarian cancer continue to emerge at a rapid pace, including several options that target the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) family of enzymes. FDA approval has been granted for several of these agents, altering the treatment landscape. In order to optimize clinical decision-making regarding medical therapies for ovarian cancer, it is imperative for clinicians to be aware of the latest data pertaining to PARP inhibition. This activity is designed to enhance knowledge of the mechanistic rationale for the application of PARP inhibitors in the treatment of patients with ovarian cancer, as well as strategies to personalize care for these patients and mitigate adverse events associated with this treatment modality. The perspectives of leading clinical experts in the management of ovarian cancer will be provided throughout this activity.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
• Discuss how care can be personalized via the use of testing strategies in BRCA-mutant and non—BRCA-mutant patient populations with ovarian cancer
• Examine the current emerging roles of PARP inhibitors (PARPis) in maintenance therapy for ovarian cancer
• Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical, surgical and radiation oncologists who treat or manage patients with ovarian cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate. This CME Conference has been approved for a maximum of 1.00 AMA PRA Category 1 Credits.
Conference Overview :
New clinical treatment options for patients with ovarian cancer continue to emerge at a rapid pace, including several options that target the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) family of enzymes. FDA approval has been granted for several of these agents, altering the treatment landscape. In order to optimize clinical decision-making regarding medical therapies for ovarian cancer, it is imperative for clinicians to be aware of the latest data pertaining to PARP inhibition. This activity is designed to enhance knowledge of the mechanistic rationale for the application of PARP inhibitors in the treatment of patients with ovarian cancer, as well as strategies to personalize care for these patients and mitigate adverse events associated with this treatment modality. The perspectives of leading clinical experts in the management of ovarian cancer will be provided throughout this activity.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
• Discuss how care can be personalized via the use of testing strategies in BRCA-mutant and non—BRCA-mutant patient populations with ovarian cancer
• Examine the current emerging roles of PARP inhibitors (PARPis) in maintenance therapy for ovarian cancer
• Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links